CervoMed (CRVO) Other Non Operating Income (2012 - 2026)
CervoMed (CRVO) posted Other Non Operating Income of -$1021.0 for Q1 2026, down 131.02% sequentially from $3291.0 in Q4 2025, and down 656.3% YoY from $183.54 in Q1 2025.
CervoMed (CRVO) Other Non Operating Income (2012 - 2026) Analysis & Trends
CervoMed has reported Other Non Operating Income for 9 years, with the latest figure at -$1021.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 656.3% year-over-year to -$1021.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9213.0 (down 740.6% YoY) and the FY2025 annual result came in at -$8327.0, down 740.26% from the prior year.
- Other Non Operating Income retreated to -$1021.0 in Q1 2026 per CRVO's latest filing, from $3291.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $4.8 million in Q3 2023 and troughed at -$620059.0 in Q4 2022.
- A 5-year average of $319407.1 and a median of -$247.0 in 2024 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2023 and 2025: Other Non Operating Income jumped 5429445.45% in 2023, then tumbled 4052.23% in 2025.
- Over 5 years, Other Non Operating Income stood at -$620059.0 in 2022, then soared by 99.9% to -$600.0 in 2023, then surged by 554.33% to $2726.0 in 2024, then gained by 20.73% to $3291.0 in 2025, then sank by 131.02% to -$1021.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$1021.0, $3291.0, and -$1227.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CervoMed | 26.64 Mn | 26.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,998.00 |
| Mar 31, 2026 | -1,021.00 |
| Dec 31, 2025 | 3,291.00 |
| Sep 30, 2025 | -1,227.00 |
| Jun 30, 2025 | -10,256.00 |
| Mar 31, 2025 | -135.00 |
| Dec 31, 2024 | 2,726.00 |
| Sep 30, 2024 | -3,440.00 |
| Jun 30, 2024 | -247.00 |
| Mar 31, 2024 | -30.00 |
| Dec 31, 2023 | -600.00 |
| Sep 30, 2023 | 4.78 Mn |
| Jun 30, 2023 | -212,211.00 |
| Mar 31, 2023 | 856,579.00 |
| Dec 31, 2022 | -620,059.00 |
| Sep 30, 2022 | -88.00 |
| Dec 31, 2015 | 1,039.00 |
| Sep 30, 2015 | 1,165.00 |
| Jun 30, 2015 | 1,633.00 |
| Mar 31, 2015 | 2,520.00 |